Wendy Stock and Geoffrey Uy were named co-chairs of the Leukemia Committee of the Alliance for Clinical Trials in Oncology.
For patients with acute lymphoblastic leukemia carrying the Philadelphia chromosome and whose disease relapsed after allogeneic hematopoietic stem cell transplantation, the two-year overall survival rate nearly doubled from 2000-2004 to 2015-2019, according to a study published in Clinical Cancer Research.
According to a study led by University of Michigan researchers, fewer than one-third of hospitals had immediate availability of all-trans retinoic acid (ATRA), which is initiated early in the treatment of acute promyelocytic leukemia to prevent major bleeding, clotting, and potential death.
Prof. Elihu (Eli) H. Estey, MD, a pioneering AML researcher, physician and scholar collapsed and died unexpectedly on Oct. 8 at his home in Seattle. He was 75.
In collaboration with Donald Pinkel’s daughter, Mary Pinkel, the Cancer History Project is preserving and republishing materials from his personal archive.
MURANO, a randomized phase III study sponsored by Abbvie, showed that patients with relapsed or refractory chronic lymphocytic leukemia achieved significantly prolonged median progression-free survival with Venclexta/Venclyxto (venetoclax) in combination with Rituxan (rituximab) [median PFS, not reached], compared with bendamustine in combination with Rituxan [median PFS, 17.0 months; hazard ratio, 0.17; 95% CI, 0.11–0.25; P<0.0001].
AbbVie published longer-term follow-up results from three phase III studies of Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: RESONATE, RESONATE-2 and HELIOS.
A phase III trial of Vyxeos Liposome for Injection demonstrated statistically significant improvements in overall survival in patients with high-risk secondary acute myeloid leukemia.
A phase III trial of Arzerra as a maintenance therapy for chronic lymphocytic leukemia met its primary endpoint of extending progression-free survival at an interim analysis.
Data from the phase III RESONATE trial showed that monotherapy ibrutinib significantly lengthened progression-free survival and overall survival compared to ofatumumab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia.
